Therapeutic effects of telmisartan on patients with mild-to-moderate essential hypertension and its safety

Objective: To evaluate the therapeutic effects of telmisartan on patients with mild-to-moderate essential hypertension. Methods: Seventy-two patients with essential hypertension were enrolled in this clinical pharmacological trial and randomly divided into telmisartan group (35 patients) and losartan group (37 patients). In the evaluating period of 8 weeks,every patients in telmisartan group took 80 mg of telmisartan and the patients in losartan group took 50 mg of losartan every morning. Their blood pressure was measured after 4 and 8 weeks of treatment. The serum level of potassium, liver function and renal function were examined before and after the trial. Results:The blood pressures of both groups were decreased significantly after 4 and 8 weeks of trial compared with those before the trial (P0.05, P0.01). The blood pressures of telmisartan group were decreased more remarkably than losartan group (P0.01,P0.001). The antihypertensive efficacy rates of telmisartan group and losartan group were 94.1% and 88.6%,respectively. The serum level of potassium, liver function and renal function had no obvious difference before and after the trial. Conclusion: Telmisartan can be used effectively and safely in anti-hypertensive medication of patients with mild-to-moderate essential hypertension.